Vahid Bemanian1, John Christopher Noone1, Torill Sauer2,3, Joel Touma4,5, Katja Vetvik3,4, Cecilia Søderberg-Naucler6, Jonas Christoffer Lindstrøm3,7, Ida Rashida Bukholm4,8,9, Vessela N Kristensen3,10, Jürgen Geisler11,12. 1. Section of Gene Technology, Akershus University Hospital, 1478, Lørenskog, Norway. 2. Department of Pathology, Akershus University Hospital, 1478, Lørenskog, Norway. 3. Institute of Clinical Medicine, University of Oslo, Campus at Akershus University Hospital, 1478, Lørenskog, Norway. 4. Department of Breast and Endocrine Surgery, Akershus University Hospital, 1478, Lørenskog, Norway. 5. Department of Oncology, Akershus University Hospital, 1478, Lørenskog, Norway. 6. Department of Medicine at Solna, Experimental Cardiovascular Research Unit and Departments of Medicine and Neurology, Center for Molecular Medicine, Karolinska Institute, 17176, Stockholm, Sweden. 7. Health Services Research Unit, Akershus University Hospital, 1478, Lørenskog, Norway. 8. Norwegian System of Compensation to Patients, Oslo, Norway. 9. The Norwegian University of Life Sciences, Ås, Norway. 10. Clinical Molecular Biology (EPIGEN), Akershus University Hospital, 1478, Lørenskog, Norway. 11. Institute of Clinical Medicine, University of Oslo, Campus at Akershus University Hospital, 1478, Lørenskog, Norway. juergen.geisler@medisin.uio.no. 12. Department of Oncology, Akershus University Hospital, 1478, Lørenskog, Norway. juergen.geisler@medisin.uio.no.
Abstract
PURPOSE: We have compared the mutational profiles of human breast cancer tumor samples belonging to all major subgroups with special emphasis on triple-negative breast cancer (TNBC). Our major goal was to identify specific mutations that could be potentially used for clinical decision making in TNBC patients. PATIENTS AND METHODS: Primary tumor specimens from 149 Norwegian breast cancer patients were available. We analyzed the tissue samples for somatic mutations in 44 relevant breast cancer genes by targeted next-generation sequencing. As a second confirmatory technique, we performed pyrosequencing on selected samples. RESULTS: We observed a distinct subgroup of TNBC patients, characterized by an almost completely lack of pathogenic somatic mutations. A point mutation in the adenoviral E1A binding protein p300 (EP300-G211S) was significantly correlated to this TNBC subgroup. The EP300-G211S mutation was exclusively found in the TNBC patients and its presence reduced the chance for other pathological somatic mutations in typical breast cancer genes investigated in our gene panel by 94.9% (P < 0.005). Interestingly, the EP300-G211S mutation also predicted a lower risk for relapses and decreased breast cancer-specific mortality during long-term follow-up of the patients. CONCLUSION: Next-generation sequencing revealed specific mutations in EP300 to be associated with the mutational patterns in typical breast cancer genes and long-term outcome of triple-negative breast cancer patients.
PURPOSE: We have compared the mutational profiles of humanbreast cancer tumor samples belonging to all major subgroups with special emphasis on triple-negative breast cancer (TNBC). Our major goal was to identify specific mutations that could be potentially used for clinical decision making in TNBC patients. PATIENTS AND METHODS: Primary tumor specimens from 149 Norwegian breast cancerpatients were available. We analyzed the tissue samples for somatic mutations in 44 relevant breast cancer genes by targeted next-generation sequencing. As a second confirmatory technique, we performed pyrosequencing on selected samples. RESULTS: We observed a distinct subgroup of TNBC patients, characterized by an almost completely lack of pathogenic somatic mutations. A point mutation in the adenoviral E1A binding protein p300 (EP300-G211S) was significantly correlated to this TNBC subgroup. The EP300-G211S mutation was exclusively found in the TNBC patients and its presence reduced the chance for other pathological somatic mutations in typical breast cancer genes investigated in our gene panel by 94.9% (P < 0.005). Interestingly, the EP300-G211S mutation also predicted a lower risk for relapses and decreased breast cancer-specific mortality during long-term follow-up of the patients. CONCLUSION: Next-generation sequencing revealed specific mutations in EP300 to be associated with the mutational patterns in typical breast cancer genes and long-term outcome of triple-negative breast cancerpatients.
Entities:
Keywords:
Breast cancer; EP300 mutations; Next-generation sequencing; Pyrosequencing; TP53; Triple-negative breast cancer